TY - STD TI - European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. Available from: http://www.easl.eu/medias/EASLimg/News/easl_recommendations_hcv_2014_full.pdf. Accessed Jan 2017. UR - http://www.easl.eu/medias/EASLimg/News/easl_recommendations_hcv_2014_full.pdf ID - ref1 ER - TY - STD TI - National Institute for Health and Care Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance [TA75]. 2004. 22 August 2016. Available from: https://www.nice.org.uk/guidance/ta75. Accessed Jan 2017. UR - https://www.nice.org.uk/guidance/ta75 ID - ref2 ER - TY - STD TI - National Institute for Health and Care Excellence. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance [TA200]. 2010. 15 August 2014. Available from: https://www.nice.org.uk/guidance/TA200. Accessed Jan 2017. UR - https://www.nice.org.uk/guidance/TA200 ID - ref3 ER - TY - JOUR AU - Petruzziello, A. AU - Marigliano, S. AU - Loquercio, G. AU - Cozzolino, A. AU - Cacciapuoti, A. PY - 2016 DA - 2016// TI - Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes JO - World J Gastroenterol VL - 22 UR - https://doi.org/10.3748/wjg.v22.i34.7824 DO - 10.3748/wjg.v22.i34.7824 ID - Petruzziello2016 ER - TY - JOUR AU - Andriulli, A. AU - Mangia, A. AU - Iacobellis, A. AU - Ippolito, A. AU - Leandro, G. AU - Zeuzem, S. PY - 2008 DA - 2008// TI - Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis JO - Aliment Pharmacol Ther VL - 28 UR - https://doi.org/10.1111/j.1365-2036.2008.03763.x DO - 10.1111/j.1365-2036.2008.03763.x ID - Andriulli2008 ER - TY - JOUR AU - Kanwal, F. AU - Kramer, J. R. AU - Ilyas, J. AU - Duan, Z. AU - El-Serag, H. B. PY - 2014 DA - 2014// TI - HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV JO - Hepatology VL - 60 UR - https://doi.org/10.1002/hep.27095 DO - 10.1002/hep.27095 ID - Kanwal2014 ER - TY - JOUR AU - Wu, C. J. AU - Roytman, M. M. AU - Hong, L. K. AU - Huddleston, J. AU - Trujillo, R. AU - Cheung, A. PY - 2015 DA - 2015// TI - Real-world experience with sofosbuvir-based regimens for chronic hepatitis C, including patients with factors previously associated with inferior treatment response JO - Hawaii J Med Public Health VL - 74 ID - Wu2015 ER - TY - STD TI - European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–94. http://doi.org/10.1016/j.jhep.2016.09.001. ID - ref8 ER - TY - STD TI - World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version April 2016. Available from: http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1. Accessed Jan 2017. UR - http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1 ID - ref9 ER - TY - STD TI - American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org/. Accessed Jan 2017. UR - http://www.hcvguidelines.org ID - ref10 ER - TY - JOUR AU - Catanese, M. T. AU - Dorner, M. PY - 2015 DA - 2015// TI - Advances in experimental systems to study hepatitis C virus in vitro and in vivo JO - Virology VL - 479–480 UR - https://doi.org/10.1016/j.virol.2015.03.014 DO - 10.1016/j.virol.2015.03.014 ID - Catanese2015 ER - TY - JOUR AU - Ampuero, J. AU - Romero-Gómez, M. AU - Reddy, K. R. PY - 2014 DA - 2014// TI - HCV genotype 3 – the new treatment challenge JO - Aliment Pharmacol Ther VL - 39 UR - https://doi.org/10.1111/apt.12646 DO - 10.1111/apt.12646 ID - Ampuero2014 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altmann, G. PY - 2009 DA - 2009// TI - The PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - PLoS Med VL - 6 UR - https://doi.org/10.1371/journal.pmed.1000097 DO - 10.1371/journal.pmed.1000097 ID - Moher2009 ER - TY - JOUR AU - Freeman, M. F. AU - Tukey, J. W. PY - 1950 DA - 1950// TI - Transformations related to the angular and the square root JO - Ann Math Statist VL - 21 UR - https://doi.org/10.1214/aoms/1177729756 DO - 10.1214/aoms/1177729756 ID - Freeman1950 ER - TY - JOUR AU - Barendregt, J. J. AU - Doi, S. A. AU - Lee, Y. Y. AU - Rosana, E. AU - Norman, R. E. AU - Vos, T. PY - 2013 DA - 2013// TI - Meta-analysis of prevalence JO - J Epidemiol Community Health VL - 67 UR - https://doi.org/10.1136/jech-2013-203104 DO - 10.1136/jech-2013-203104 ID - Barendregt2013 ER - TY - JOUR AU - Higgins, J. P. T. AU - Thompson, S. G. PY - 2002 DA - 2002// TI - Quantifying heterogeneity in a meta-analysis JO - Stat Med VL - 21 UR - https://doi.org/10.1002/sim.1186 DO - 10.1002/sim.1186 ID - Higgins2002 ER - TY - JOUR AU - Higgins, J. P. T. AU - Thompson, S. G. AU - Deeks, J. J. AU - Altman, D. G. PY - 2003 DA - 2003// TI - Measuring inconsistency in meta-analyses JO - BMJ VL - 327 UR - https://doi.org/10.1136/bmj.327.7414.557 DO - 10.1136/bmj.327.7414.557 ID - Higgins2003 ER - TY - JOUR AU - Clopper, C. J. AU - Pearson, E. S. PY - 1934 DA - 1934// TI - The use of confidence or fiducial limits illustrated in the case of the ‘binomial JO - Biometrika VL - 26 UR - https://doi.org/10.1093/biomet/26.4.404 DO - 10.1093/biomet/26.4.404 ID - Clopper1934 ER - TY - JOUR AU - Swallow, E. AU - Song, J. AU - Yuan, Y. AU - Kalsekar, A. AU - Kelley, C. AU - Peeples, M. PY - 2016 DA - 2016// TI - Daclatasvir and sofosbuvir versus sofosbuvir and ribavirin in patients with chronic hepatitis C coinfected with HIV: a matching-adjusted indirect comparison JO - Clin Ther VL - 38 UR - https://doi.org/10.1016/j.clinthera.2015.12.017 DO - 10.1016/j.clinthera.2015.12.017 ID - Swallow2016 ER - TY - JOUR AU - Kohli, A. AU - Shaffer, A. AU - Sherman, A. AU - Kottilil, S. PY - 2014 DA - 2014// TI - Treatment of hepatitis C: a systematic review JO - JAMA VL - 312 UR - https://doi.org/10.1001/jama.2014.7085 DO - 10.1001/jama.2014.7085 ID - Kohli2014 ER - TY - STD TI - Merck, 2017. Merck Discontinues MK-3682B and MK-3682C Development Programs. Available from: http://www.mrknewsroom.com/news-release/corporate-news/merck-discontinues-mk-3682b-and-mk-3682c-development-programs. Accessed Oct 2017. UR - http://www.mrknewsroom.com/news-release/corporate-news/merck-discontinues-mk-3682b-and-mk-3682c-development-programs ID - ref21 ER - TY - JOUR AU - Jacobson, I. M. AU - Gordon, S. C. AU - Kowdley, K. V. AU - Yoshida, E. M. AU - Rodriguez-Torres, M. AU - Sulkowski, M. PY - 2013 DA - 2013// TI - Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1214854 DO - 10.1056/NEJMoa1214854 ID - Jacobson2013 ER - TY - JOUR AU - Lawitz, E. L. AU - Mangia, A. AU - Wyles, D. AU - Rodriguez-Torres, M. AU - Hassanein, T. AU - Gordon, S. C. PY - 2013 DA - 2013// TI - Sofosbuvir for previously untreated chonic hepatitis C infection JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1214853 DO - 10.1056/NEJMoa1214853 ID - Lawitz2013 ER - TY - JOUR AU - Younossi, Z. M. AU - Stepanova, M. AU - Sulkowski, M. AU - Naggie, S. AU - Puoti, M. AU - Orkin, C. PY - 2015 DA - 2015// TI - Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes JO - J Infect Dis VL - 212 UR - https://doi.org/10.1093/infdis/jiv005 DO - 10.1093/infdis/jiv005 ID - Younossi2015 ER - TY - JOUR AU - Curry, M. P. AU - O'Leary, J. G. AU - Bzowej, N. AU - Muir, A. J. AU - Korenblat, K. M. AU - Fenkel, J. M. PY - 2015 DA - 2015// TI - Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1512614 DO - 10.1056/NEJMoa1512614 ID - Curry2015 ER - TY - STD TI - Foster GR, Thompson AJ, Ruane PJ, Borgia S, Dore G, Workowski K, et al. A randomized phase 3 trial of sofosbuvir/velpatasvir/voxilaprevir for 8 weeks and sofosbuvir/velpatasvir for 12 weeks for patients with genotype 3 HCV infection and cirrhosis: The POLARIS-3 Study. 67th Meeting of the American Association for the Study of Liver Diseases: Liver Meeting 2016. Boston, November 11–15, 2016. Abstract 258. ID - ref26 ER - TY - STD TI - Kwo PY, Wyles DL, Wang S, Poordad F, Gane E, Maliakkal B, et al. 100% SVR12 with ABT-493 and ABT-530 with or without ribavirin in treatment-naïve HCV genotype 3-infected patients with cirrhosis. 51st Annual Meeting of the European Association for the Study of the Liver: Barcelona April 13–17, 2016. Abstract LB01. ID - ref27 ER - TY - STD TI - Foster GR, Cooper C, Molina J-M, Naggie S, Huang KC, Osinusi A, et al. C-ISLE: Grazoprevir/elbasvir plus sofosbuvir in treatment-naïve and treatment-experienced HCV GT3 cirrhotic patients treated for 8, 12 or 16 weeks. 67th Meeting of the American Association for the Study of Liver Diseases: Liver Meeting 2016. Boston, November 11-15, 2016. Abstract 74. ID - ref28 ER - TY - STD TI - Janssen, 2017. Janssen to Discontinue Hepatitis C Development Program. Available from: http://www.janssen.com/janssen-discontinue-hepatitis-c-development-program. Accessed Oct 2017. UR - http://www.janssen.com/janssen-discontinue-hepatitis-c-development-program ID - ref29 ER - TY - JOUR AU - Bruchfeld, A. AU - Roth, D. AU - Martin, P. AU - Nelson, D. R. AU - Pol, S. AU - Londoño, M. C. PY - 2017 DA - 2017// TI - Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet JO - Gastroenterol Hepatol VL - 2 ID - Bruchfeld2017 ER - TY - JOUR AU - Cholongitas, E. AU - Pipili, C. AU - Papatheodoridis, G. V. PY - 2017 DA - 2017// TI - Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation JO - World J Hepatol VL - 9 UR - https://doi.org/10.4254/wjh.v9.i4.180 DO - 10.4254/wjh.v9.i4.180 ID - Cholongitas2017 ER - TY - JOUR AU - Colombo, M. AU - Aghemo, A. AU - Liu, H. AU - Zhang, J. AU - Dvory-Sobol, H. AU - Hyland, R. PY - 2017 DA - 2017// TI - Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial JO - Ann Intern Med VL - 166 UR - https://doi.org/10.7326/M16-1205 DO - 10.7326/M16-1205 ID - Colombo2017 ER - TY - JOUR AU - Desnoyer, A. AU - Pospai, D. AU - Lê, M. P. AU - Gervais, A. AU - Heurgué-Berlot, A. AU - Laradi, A. PY - 2016 DA - 2016// TI - Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C JO - J Hepatol VL - 65 UR - https://doi.org/10.1016/j.jhep.2016.02.044 DO - 10.1016/j.jhep.2016.02.044 ID - Desnoyer2016 ER - TY - STD TI - Fabrizi F, Donato FM, and Messa P. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis. Int J Artif Organs. 8 July 2017 [epub ahead of print]. doi:10.5301/ijao.5000613 ID - ref34 ER - TY - JOUR AU - Pockros, P. J. AU - Reddy, K. R. AU - Mantry, P. S. AU - Cohen, E. AU - Bennett, M. AU - Sulkowski, M. S. PY - 2016 DA - 2016// TI - Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease JO - Gastroenterology VL - 150 UR - https://doi.org/10.1053/j.gastro.2016.02.078 DO - 10.1053/j.gastro.2016.02.078 ID - Pockros2016 ER - TY - STD TI - Reddy KR, Roth D, Bruchfeld A, Hwang P, Haber B, Robertson MN, et al. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatol Res. 23 March 2017 [epub ahead of print]. doi:10.1111/hepr.12899. ID - ref36 ER - TY - JOUR AU - Roth, D. AU - Nelson, D. R. AU - Bruchfeld, A. AU - Liapakis, A. AU - Silva, M. AU - Monsour, H. PY - 2015 DA - 2015// TI - Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study JO - Lancet VL - 386 UR - https://doi.org/10.1016/S0140-6736(15)00349-9 DO - 10.1016/S0140-6736(15)00349-9 ID - Roth2015 ER - TY - JOUR AU - Saxena, V. AU - Khungar, V. AU - Verna, E. C. AU - Levitsky, J. AU - Brown, R. S. AU - Hassan, M. A. PY - 2017 DA - 2017// TI - Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study JO - Hepatology VL - 66 UR - https://doi.org/10.1002/hep.29258 DO - 10.1002/hep.29258 ID - Saxena2017 ER - TY - STD TI - AASLD and IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2017. Available at: http://hcvguidelines.org/. Accessed Oct 2017. UR - http://hcvguidelines.org/ ID - ref39 ER - TY - STD TI - Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, et al. Grazoprevir, ruzasvir, and uprifosbuvir for HCV after NS5A treatment failure. Hepatology. 7 July 2017 [epub ahead of print]. doi:10.1002/hep.29358. ID - ref40 ER - TY - STD TI - Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir/pibrentasvir for HCV genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase III clinical trial. Hepatology. 19 September 2017 [epub ahead of print]. doi:10.1002/hep.29541. ID - ref41 ER - TY - JOUR AU - Voaklander, R. AU - Jacobson, I. M. PY - 2017 DA - 2017// TI - Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C JO - Expert Rev Gastroenterol Hepatol VL - 11 UR - https://doi.org/10.1080/17474124.2017.1351295 DO - 10.1080/17474124.2017.1351295 ID - Voaklander2017 ER - TY - JOUR AU - Tong, L. AU - Yu, W. AU - Chen, L. AU - Selyutin, O. AU - Dwyer, M. P. AU - Nair, A. G. PY - 2017 DA - 2017// TI - Discovery of ruzasvir (mk-8408): a potent, pan-genotype HCV NS5A inhibitor with optimized activity against common resistance-associated polymorphisms JO - J Med Chem VL - 60 UR - https://doi.org/10.1021/acs.jmedchem.6b01310 DO - 10.1021/acs.jmedchem.6b01310 ID - Tong2017 ER - TY - JOUR AU - Poordad, F. AU - Felizarta, F. AU - Asatryan, A. AU - Sulkowski, M. S. AU - Reindollar, R. W. AU - Landis, C. S. PY - 2017 DA - 2017// TI - Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment JO - Hepatology VL - 66 UR - https://doi.org/10.1002/hep.29081 DO - 10.1002/hep.29081 ID - Poordad2017 ER - TY - JOUR AU - Molino, S. AU - Martin, M. T. PY - 2017 DA - 2017// TI - Hepatitis c virus resistance testing in genotype 1: the changing role in clinical utility JO - Ann Pharmacother VL - 51 UR - https://doi.org/10.1177/1060028017704857 DO - 10.1177/1060028017704857 ID - Molino2017 ER - TY - JOUR AU - Lawitz, E. AU - Poordad, F. AU - Wells, J. AU - Hyland, R. H. AU - Yang, Y. AU - Dvory-Sobol, H. PY - 2017 DA - 2017// TI - Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus JO - Hepatology VL - 65 UR - https://doi.org/10.1002/hep.29130 DO - 10.1002/hep.29130 ID - Lawitz2017 ER - TY - STD TI - Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, et al. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 9 August 2017 [epub ahead of print]. doi:10.1016/S2468-1253(17)30163-2. ID - ref47 ER - TY - JOUR AU - Gane, E. J. AU - Shiffman, M. L. AU - Etzkorn, K. AU - Morelli, G. AU - Stedman, C. A. M. AU - Davis, M. N. PY - 2017 DA - 2017// TI - Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen JO - Hepatology VL - 66 UR - https://doi.org/10.1002/hep.29256 DO - 10.1002/hep.29256 ID - Gane2017 ER - TY - JOUR AU - Bourlière, M. AU - Gordon, S. C. AU - Flamm, S. L. AU - Cooper, C. L. AU - Ramji, A. AU - Tong, M. PY - 2017 DA - 2017// TI - Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1613512 DO - 10.1056/NEJMoa1613512 ID - Bourlière2017 ER - TY - JOUR AU - Gane, E. J. AU - Schwabe, C. AU - Hyland, R. H. AU - Yang, Y. AU - Svarovskaia, E. AU - Stamm, L. M. PY - 2016 DA - 2016// TI - Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with hepatitis C virus genotype 1 or 3 infections JO - Gastroenterology VL - 151 UR - https://doi.org/10.1053/j.gastro.2016.05.021 DO - 10.1053/j.gastro.2016.05.021 ID - Gane2016 ER -